Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo, dated March 12, 2003, addresses a restatement of accounts by its partner, Bristol-Myers Squibb (BMS), for the years 1999 to 2002. The filing clarifies the impact of this restatement on Sanofi-Synthelabo's reported sales and earnings for the products Plavix and Avapro.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it focuses on accounting methodology and the relationship between invoicing and final demand (prescriptions) for 2002.
- Revenue Recognition: Sanofi-Synthelabo confirms that 2002 sales figures for Plavix and Avapro correspond solely to invoicing registered by BMS in the United States during 2002.
- Inventory Trends: The increase in invoicing for 2002 was inferior to the increase in final demand, indicating a decline in the inventories-to-sales ratio for that year.
- Earnings Basis: Consolidated earnings for 2002 regarding these products are based solely on invoicing for the year, in compliance with French accounting principles.
Material Changes Versus Prior Period
Sanofi-Synthelabo states there is no need to modify its 2002 accounts published on February 18, 2003, despite BMS's restatement. The restatement by BMS included invoicing registered in the period 1999 to 2001, which Sanofi-Synthelabo clarifies was not included in its own 2002 reporting.
Guidance, Outlook, and Risks
Outlook: Management confirms that invoicing for Plavix and Avapro in 2003 is expected to evolve in line with final demand. There is no change to the growth forecasts for sales and net earnings per share for 2003, as previously announced by CEO Jean-François Dehecq on February 18, 2003.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks cited include:
- Ability to expand profitably in the United States.
- Success of research and development programs.
- Protection of intellectual property rights.
- Risks associated with healthcare cost reimbursement and pricing reforms, particularly in the U.S. and France.
Investor Verification Checklist
- Verify the specific sales and net earnings per share growth forecasts announced on February 18, 2003, to confirm the baseline for the 2003 outlook.
- Review the February 18, 2003, press release to confirm the 2002 consolidated earnings figures that Sanofi-Synthelabo states do not require modification.
- Monitor future filings for updates on the U.S. expansion strategy and R&D pipeline success, as these are cited as primary uncertainties.